Aspirin Use Guidelines for Cardiovascular Prevention

Secondary Prevention

• For patients with established cardiovascular disease, the American College of Cardiology recommends aspirin 75-100 mg daily as lifelong therapy after completion of dual antiplatelet therapy 1
• Aspirin is indicated for all patients with previous myocardial infarction, coronary revascularization, or significant obstructive coronary artery disease on imaging 1
• The optimal dose range is 75-100 mg daily 1
• For patients with diabetes and established atherosclerotic cardiovascular disease, aspirin 75-162 mg daily is recommended 1
• In secondary prevention, the benefits far outweigh bleeding risks 1

Primary Prevention

• For adults aged 40-59 years with ≥10% 10-year ASCVD risk and no increased bleeding risk, the American Heart Association recommends considering low-dose aspirin (75-100 mg daily), but the net benefit is small 2
• Consider aspirin only if 10-year ASCVD risk is ≥10% and patient is not at increased bleeding risk 2
• The 2019 ACC/AHA guideline gives this a Class IIb recommendation (may be considered) 2

Absolute Contraindications

• Do not prescribe aspirin for primary prevention in patients at increased bleeding risk, regardless of cardiovascular risk, according to the American Heart Association 2
• History of gastrointestinal bleeding or peptic ulcer disease is a contraindication 2, 1
• Age >70 years is a contraindication for primary prevention 2, 1
• Thrombocytopenia or coagulopathy is a contraindication 2
• Chronic kidney disease is a contraindication 2
• Concurrent use of NSAIDs, steroids, anticoagulants (warfarin, DOACs) is a contraindication 2, 1
• Uncontrolled hypertension is a contraindication 3, 1

Bleeding Risk Quantification

• Major gastrointestinal bleeding occurs in 2-4 per 1,000 middle-aged adults over 5 years (4-12 per 1,000 in older adults) 4, 5, 6, 1
• Hemorrhagic stroke increases by 0-2 per 1,000 persons over 5 years 4, 5, 6, 1
• Relative risk of major GI bleeding is 1.6 even with low doses 1

Optimal Dosing

• The recommended dose for both primary and secondary prevention is 75-100 mg daily, according to the American Heart Association 2, 1
• Doses of 75-162 mg daily are acceptable 1

Special Populations

• For hypertensive patients aged ≥50 years with controlled blood pressure and target organ damage, diabetes, or 10-year CVD risk >15%, consider aspirin 75-81 mg daily for primary prevention 1
• For diabetic patients aged ≥50 years with at least one additional major cardiovascular risk factor, aspirin 75-162 mg daily may be considered for primary prevention 1

Clinical Pitfalls to Avoid

• Do not prescribe aspirin for low-risk individuals: Those with <10% 10-year ASCVD risk derive minimal benefit that is outweighed by bleeding risk 1
• Do not ignore bleeding risk factors: Always assess for history of GI bleeding, concurrent anticoagulation, and uncontrolled hypertension before prescribing 2, 1
• Do not use aspirin as monotherapy for acute coronary syndrome: Dual antiplatelet therapy is required 7, 1
• Do not continue dual antiplatelet therapy indefinitely post-PCI: Transition to aspirin monotherapy after 12 months unless specific indications exist 7

Aspirin for Primary Prevention: Evidence‑Based Recommendations

Eligibility and Decision‑Making

• In adults aged 40‑59 years without established ASCVD, aspirin 75‑100 mg daily may be considered only when the 10‑year ASCVD risk is ≥10 %, no bleeding risk factors are present, and the patient consents after shared decision‑making. This is a Class IIb (weak) recommendation with a small net benefit—the number of cardiovascular events prevented is roughly equal to the number of major bleeding episodes induced. 8

• The 2016 U.S. Preventive Services Task Force (USPSTF) concluded with moderate certainty that aspirin provides a small to moderate net benefit in select primary‑prevention populations. 8

Age‑Based Contraindications

• Age ≥ 70 years is considered an absolute contraindication for primary‑prevention aspirin because harms outweigh any potential benefits. (Derived from the age‑stratified algorithm; citation 8 supports the overall recommendation framework.) 8

Dose Selection

• When aspirin is indicated for primary prevention, the lowest effective dose (75‑100 mg daily; 81 mg in the United States) should be used. Doses above this range (up to 162 mg) do not confer additional cardiovascular protection but significantly increase major bleeding risk. This conclusion is based on trial data demonstrating no incremental benefit with higher doses. [9][10]

Historical Guideline Evolution

These shifts reflect emerging evidence that the incremental cardiovascular benefit of aspirin in low‑ to moderate‑risk adults is offset by a comparable increase in major bleeding events. [8][9]10